Production (Stage)
Amphastar Pharmaceuticals, Inc.
AMPH
$24.47
$0.271.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 170.53M | 186.98M | 188.82M | 179.39M | 157.63M |
| Total Other Revenue | -- | -455.00K | 2.40M | 3.01M | 14.21M |
| Total Revenue | 170.53M | 186.52M | 191.21M | 182.39M | 171.84M |
| Cost of Revenue | 85.28M | 99.88M | 89.27M | 87.23M | 81.74M |
| Gross Profit | 85.25M | 86.65M | 101.94M | 95.17M | 90.10M |
| SG&A Expenses | 27.86M | 23.36M | 23.82M | 22.30M | 25.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.24M | 141.38M | 134.17M | 127.18M | 123.83M |
| Operating Income | 37.29M | 45.14M | 57.05M | 55.22M | 48.01M |
| Income Before Tax | 30.86M | 43.96M | 47.68M | 50.24M | 47.30M |
| Income Tax Expenses | 5.58M | 6.00M | 7.25M | 12.29M | 4.13M |
| Earnings from Continuing Operations | 25.29M | 37.96M | 40.43M | 37.95M | 43.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.29M | 37.96M | 40.43M | 37.95M | 43.18M |
| EBIT | 37.29M | 45.14M | 57.05M | 55.22M | 48.01M |
| EBITDA | 50.90M | 58.58M | 70.45M | 68.37M | 60.99M |
| EPS Basic | 0.53 | 0.79 | 0.83 | 0.78 | 0.90 |
| Normalized Basic EPS | 0.40 | 0.57 | 0.61 | 0.64 | 0.61 |
| EPS Diluted | 0.51 | 0.74 | 0.78 | 0.73 | 0.81 |
| Normalized Diluted EPS | 0.39 | 0.54 | 0.57 | 0.60 | 0.56 |
| Average Basic Shares Outstanding | 47.64M | 47.98M | 48.62M | 48.91M | 48.21M |
| Average Diluted Shares Outstanding | 49.89M | 51.31M | 51.86M | 52.05M | 53.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |